<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALINIA- nitazoxanide tablet </strong><br><strong>ALINIA- nitazoxanide powder, for suspension </strong><br>Romark Laboratories, LC<br></p></div>
<h1>Alinia<span class="Sup">®</span>
(nitazoxanide) Tablets<br>(nitazoxanide) for Oral Suspension
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Alinia Tablets and Alinia for Oral Suspension contain the active ingredient, nitazoxanide, a synthetic antiprotozoal agent for oral administration. Nitazoxanide is a light yellow crystalline powder. It is poorly soluble in ethanol and practically insoluble in water. Chemically, nitazoxanide is 2-acetyloxy-<span class="Italics">N</span>-(5-nitro-2-thiazolyl)benzamide. The molecular formula is C<span class="Sub">12</span>H<span class="Sub">9</span>N<span class="Sub">3</span>O<span class="Sub">5</span>S and the molecular weight is 307.3. The structural formula is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56b1575a-dff4-4c5a-a159-2f858e7a0cb8&amp;name=ali01-0010-01.jpg">
</div>
<p>Alinia Tablets contain 500 mg of nitazoxanide and the following inactive ingredients: maize starch, pregelatinized corn starch, hydroxypropyl methylcellulose, sucrose, sodium starch glycollate, talc, magnesium stearate, soy lecithin, polyvinyl alcohol, xanthan gum, titanium dioxide, FD&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Yellow No. 6 Aluminum Lake, and FD&amp;C Blue No. 2 Aluminum Lake.
</p>
<p>Alinia for Oral Suspension, when reconstituted with 48 mL of water, produces 60 mL of a homogeneous suspension with a pink color that contains 100 mg nitazoxanide per 5 mL and the following inactive ingredients: sodium benzoate, sucrose, xanthan gum, microcrystalline cellulose and carboxymethylcellulose sodium, anhydrous citric acid, sodium citrate dihydrate, maltodextrin, modified food starch, triacetin, FD&amp;C Red #40 and artificial strawberry flavoring.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span>: Following oral administration of Alinia Tablets or Oral Suspension, maximum plasma concentrations of the active metabolites tizoxanide and tizoxanide glucuronide are observed within 1-4 hours. The parent nitazoxanide is not detected in plasma. Pharmacokinetic parameters of tizoxanide and tizoxanide glucuronide are shown in <a href="#t1">Tables 1</a> and <a href="#t2">2</a> below.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1. Mean (±SD) plasma pharmacokinetic parameter values following administration of a single dose of one 500 mg Alinia Tablet with food to subjects ≥12 years of age
</span></caption>
<col align="left" width="16.386%">
<col align="left" width="13.114%">
<col align="left" width="11.486%">
<col align="left" width="13.114%">
<col align="left" width="13.114%">
<col align="left" width="11.486%">
<col align="left" width="21.300%">
<tfoot><tr class="First Last"><td align="left" colspan="7" valign="top"><p class="First Footnote">* T<span class="Sub">max</span> is given as a Mean (Range)
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="justify" valign="top"></td>
<td class="Toprule" align="center" colspan="3" valign="top">Tizoxanide
</td>
<td class="Toprule" align="center" colspan="3" valign="top">Tizoxanide glucuronide
</td>
</tr>
<tr>
<td class="Botrule" align="justify" valign="bottom">Age
</td>
<td class="Botrule" align="center" valign="bottom">C<span class="Sub">max</span><br>(μg/mL)
</td>
<td class="Botrule" align="center" valign="bottom">
<span class="Sup">*</span>T<span class="Sub">max</span><br>(hr)
</td>
<td class="Botrule" align="center" valign="bottom">AUC<span class="Sub">τ</span><br>(μg•hr/mL)
</td>
<td class="Botrule" align="center" valign="bottom">C<span class="Sub">max</span><br>(μg/mL)
</td>
<td class="Botrule" align="center" valign="bottom">
<span class="Sup">*</span>T<span class="Sub">max</span><br>(hr)
</td>
<td class="Botrule" align="center" valign="bottom">AUC<span class="Sub">τ</span><br>(μg•hr/mL)
</td>
</tr>
<tr>
<td align="justify" valign="top">12-17 years
</td>
<td align="center" valign="top">9.1 (6.1)
</td>
<td align="center" valign="top">4.0 (1-4)
</td>
<td align="center" valign="top">39.5 (24.2)
</td>
<td align="center" valign="top">7.3 (1.9)
</td>
<td align="center" valign="top">4.0 (2-8)
</td>
<td align="center" valign="top">46.5 (18.2)
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="justify" valign="top">≥18 years
</td>
<td class="Botrule" align="center" valign="top">10.6 (2.0)
</td>
<td class="Botrule" align="center" valign="top">3.0 (2-4)
</td>
<td class="Botrule" align="center" valign="top">41.9 (6.0)
</td>
<td class="Botrule" align="center" valign="top">10.5 (1.4)
</td>
<td class="Botrule" align="center" valign="top">4.5 (4-6)
</td>
<td class="Botrule" align="center" valign="top">63.0 (12.3)
</td>
</tr>
</tbody>
</table>
<a name="t2"></a><table width="100%">
<caption><span>Table 2. Mean (±SD) plasma pharmacokinetic parameter values following administration of a single dose of Alinia for Oral Suspension with food to subjects ≥1 year of age
</span></caption>
<col align="left" width="13.114%">
<col align="left" width="9.839%">
<col align="left" width="13.114%">
<col align="left" width="11.476%">
<col align="left" width="13.114%">
<col align="left" width="13.114%">
<col align="left" width="13.114%">
<col align="left" width="13.114%">
<tfoot><tr class="First Last"><td align="left" colspan="8" valign="top"><p class="First Footnote">* T<span class="Sub">max</span> is given as a Mean (Range)
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="justify" valign="top"></td>
<td class="Toprule" align="center" colspan="4" valign="top">Tizoxanide
</td>
<td class="Toprule" align="center" colspan="3" valign="top">Tizoxanide glucuronide
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">
<br>Age
</td>
<td class="Botrule" align="left" valign="top">
<br>Dose
</td>
<td class="Botrule" align="center" valign="top">C<span class="Sub">max</span><br>(μg/mL)
</td>
<td class="Botrule" align="center" valign="top">
<span class="Sup">*</span>T<span class="Sub">max</span><br>(hr)
</td>
<td class="Botrule" align="center" valign="top">AUC<span class="Sub">inf</span><br>(μg•hr/mL)
</td>
<td class="Botrule" align="center" valign="top">C<span class="Sub">max</span><br>(μg/mL)
</td>
<td class="Botrule" align="center" valign="top">
<span class="Sup">*</span>T<span class="Sub">max</span><br>(hr)
</td>
<td class="Botrule" align="center" valign="top">AUC<span class="Sub">inf</span><br>(μg•hr/mL)
</td>
</tr>
<tr>
<td align="justify" valign="top">1-3 years
</td>
<td align="center" valign="top">100 mg
</td>
<td align="center" valign="top">3.11 (2.0)
</td>
<td align="center" valign="top">3.5 (2-4)
</td>
<td align="center" valign="top">11.7 (4.46)
</td>
<td align="center" valign="top">3.64 (1.16)
</td>
<td align="center" valign="top">4.0 (3-4)
</td>
<td align="center" valign="top">19.0 (5.03)
</td>
</tr>
<tr>
<td align="justify" valign="top">4-11 years
</td>
<td align="center" valign="top">200 mg
</td>
<td align="center" valign="top">3.00 (0.99)
</td>
<td align="center" valign="top">2.0 (1-4)
</td>
<td align="center" valign="top">13.5 (3.3)
</td>
<td align="center" valign="top">2.84 (0.97)
</td>
<td align="center" valign="top">4.0 (2-4)
</td>
<td align="center" valign="top">16.9 (5.00)
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="justify" valign="top">≥18 years
</td>
<td class="Botrule" align="center" valign="top">500 mg
</td>
<td class="Botrule" align="center" valign="top">5.49 (2.06)
</td>
<td class="Botrule" align="center" valign="top">2.5 (1-5)
</td>
<td class="Botrule" align="center" valign="top">30.2 (12.3)
</td>
<td class="Botrule" align="center" valign="top">3.21 (1.05)
</td>
<td class="Botrule" align="center" valign="top">4.0 (2.5-6)
</td>
<td class="Botrule" align="center" valign="top">22.8 (6.49)
</td>
</tr>
</tbody>
</table>
<p>Alinia for Oral Suspension is not bioequivalent to Alinia Tablets. The relative bioavailability of the suspension compared to the tablet was 70%.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-2.2"></a><p></p>
<p class="First"><span class="Italics">Effect of Food:</span> When Alinia Tablets are administered with food, the AUC<span class="Sub">t</span> of tizoxanide and tizoxanide glucuronide in plasma is increased almost two-fold and the C<span class="Sub">max</span> is increased by almost 50%.
</p>
<p>When Alinia for Oral Suspension was administered with food, the AUC<span class="Sub">t</span> of tizoxanide and tizoxanide glucuronide increased by about 45-50% and the C<span class="Sub">max</span> increased by ≤10%.
</p>
<p>Alinia Tablets and for Oral Suspension were administered with food in clinical trials and hence they are recommended to be administered with food (see <span class="Bold"><a href="#s36">DOSAGE AND ADMINISTRATION</a></span>).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Italics">Multiple dosing:</span> Following oral administration of a single Alinia Tablet every 12 hours for 7 consecutive days, there was no significant accumulation of nitazoxanide metabolites tizoxanide or tizoxanide glucuronide detected in plasma.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.3"></a><p></p>
<p class="First"><span class="Bold">Distribution:</span> In plasma, more than 99% of tizoxanide is bound to proteins.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.4"></a><p></p>
<p class="First"><span class="Bold">Metabolism</span>: Following oral administration in humans, nitazoxanide is rapidly hydrolyzed to an active metabolite, tizoxanide (desacetyl-nitazoxanide). Tizoxanide then undergoes conjugation, primarily by glucuronidation. <span class="Italics">In vitro</span> metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.5"></a><p></p>
<p class="First"><span class="Bold">Elimination</span>: Tizoxanide is excreted in the urine, bile and feces, and tizoxanide glucuronide is excreted in urine and bile. Approximately two-thirds of the oral dose of nitazoxanide is excreted in the feces and one-third in the urine.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.6"></a><p></p>
<h2>Special Populations
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.6.1"></a><p></p>
<p class="First"><span class="Italics">Patients with Impaired Hepatic and/or Renal Function:</span> The pharmacokinetics of nitazoxanide in patients with impaired hepatic and/or renal function has not been studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.6.2"></a><p></p>
<p class="First"><span class="Italics">Geriatric Patients:</span> The pharmacokinetics of nitazoxanide in geriatric patients has not been studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.6.3"></a><p></p>
<p class="First"><span class="Italics">Pediatric Patients:</span> The pharmacokinetics of nitazoxanide following administration of Alinia Tablets in pediatric patients less than 12 years of age has not been studied. The pharmacokinetics of nitazoxanide following administration of Alinia for Oral Suspension in pediatric patients less than 1 year of age has not been studied.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="s13"></a><a name="section-3"></a><p></p>
<h1>MICROBIOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s14"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action
</h2>
<p class="First">The antiprotozoal activity of nitazoxanide is believed to be due to interference with the <span class="product-label-link" type="condition" conceptid="4029769" conceptname="Pyruvic acid">pyruvate</span>:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic energy metabolism. Studies have shown that the PFOR enzyme from <span class="Italics">Giardia lamblia</span> directly reduces nitazoxanide by transfer of electrons in the absence of ferredoxin. The DNA-derived PFOR protein sequence of <span class="Italics">Cryptosporidium parvum</span> appears to be similar to that of <span class="Italics">Giardia lamblia</span>. Interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-3.1.1"></a><p></p>
<h3>Activity <span class="Italics">in vitro</span>
</h3>
<p class="First">Nitazoxanide and its metabolite, tizoxanide, are active <span class="Italics">in vitro</span> in inhibiting the growth of (i) sporozoites and oocysts of <span class="Italics">Cryptosporidium parvum</span> and (ii) trophozoites of <span class="Italics">Giardia lamblia</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-3.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span>
</h3>
<p class="First">A potential for development of resistance by <span class="Italics">Cryptosporidium parvum</span> or <span class="Italics">Giardia lamblia</span> to nitazoxanide has not been examined.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-3.2"></a><p></p>
<h2>Susceptibility Tests:
</h2>
<p class="First">For protozoa such as <span class="Italics">Cryptosporidium parvum</span> and <span class="Italics">Giardia lamblia</span>, standardized tests for use in clinical microbiology laboratories are not available.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s18"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> caused by <span class="Italics">Giardia lamblia</span> or <span class="Italics">Cryptosporidium parvum:</span>
</h2>
<p class="First">Alinia for Oral Suspension (patients 1 year of age and older) and Alinia Tablets (patients 12 years and older) are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Giardia lamblia</span> or <span class="Italics">Cryptosporidium parvum</span>.
</p>
<p>Alinia for Oral Suspension and Alinia Tablets have not been shown to be superior to placebo for the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Cryptosporidium parvum</span> in HIV-infected or immunodeficient patients (see <span class="Bold"><a href="#s42">CLINICAL STUDIES</a></span>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s20"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">Alinia Tablets and Alinia for Oral Suspension are contraindicated in patients with a prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to nitazoxanide or any other ingredient in the formulations.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s21"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s22"></a><a name="section-6.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> The pharmacokinetics of nitazoxanide in patients with compromised renal or hepatic function have not been studied. Therefore, nitazoxanide must be administered with caution to patients with hepatic and biliary disease, to patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> and to patients with combined renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s23"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients
</h2>
<p class="First">Alinia Tablets and Alinia for Oral Suspension should be taken with food.
</p>
<p>Diabetic patients and caregivers should be aware that the oral suspension contains 1.48 grams of sucrose per 5 mL.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s24"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions
</h2>
<p class="First">Tizoxanide is highly bound to plasma protein (&gt;99.9%). Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin). <span class="Italics">In vitro</span> metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes. Although no drug-drug interaction studies have been conducted <span class="Italics">in vivo</span>, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s25"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Long-term carcinogenicity studies have not been conducted.
</p>
<p>Nitazoxanide was not genotoxic in the Chinese hamster ovary (CHO) cell chromosomal aberration assay or the mouse micronucleus assay. Nitazoxanide was genotoxic in 1 tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> (TA 100) in the Ames bacterial mutation assay.
</p>
<p>Nitazoxanide did not adversely affect male or female fertility in the rat at 2,400 mg/kg/day (approximately 20 times the clinical adult dose adjusted for body surface area).
</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="s26"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy: Teratogenic Effects
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-6.5.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category B</span>: Reproduction studies have been performed at doses up to 3,200 mg/kg/day in rats (approximately 26 times the clinical adult dose adjusted for body surface area) and 100 mg/kg/day in rabbits (approximately 2 times the clinical adult dose adjusted for surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to nitazoxanide. There are, however, no adequate and well-controlled studies in pregnant women.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s28"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">It is not known whether nitazoxanide is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nitazoxanide is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s29"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">A single Alinia Tablet contains a greater amount of nitazoxanide than is recommended for pediatric dosing and should therefore not be used in pediatric patients 11 years or younger. Alinia for Oral Suspension should be used for dosing nitazoxanide in pediatric patients (see <span class="Bold"><a href="#s36">DOSAGE AND ADMINISTRATION</a></span>).
</p>
<p>Safety and effectiveness of Alinia for Oral Suspension in pediatric patients less than 1 year of age have not been studied.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s30"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use
</h2>
<p class="First">Clinical studies of Alinia Tablets and Alinia for Oral Suspension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients should be considered when prescribing Alinia Tablets and Alinia for Oral Suspension. As stated in the <span class="Bold"><a href="#s21">PRECAUTIONS</a></span> section, this therapy must be administered with caution to patients with renal and or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-6.9"></a><p></p>
<h2>HIV-Infected or Immunodeficient Patients
</h2>
<p class="First">Alinia Tablets and Alinia for Oral Suspension have not been studied for the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Giardia lamblia</span> in HIV-infected or immunodeficient patients. Alinia Tablets and Alinia for Oral Suspension have not been shown to be superior to placebo for the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Cryptosporidium parvum</span> in HIV-infected or immunodeficient patients (see <span class="Bold"><a href="#s42">CLINICAL STUDIES</a></span>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s32"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">Alinia Tablets:</span> In controlled and uncontrolled clinical studies of 1,657 HIV-uninfected patients age 12 years and older who received various dosage regimens of Alinia Tablets, the most common adverse events reported regardless of causality assessment were: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (6.6%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (4.2%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (3.1%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3.0%). In placebo-controlled clinical trials using the recommended dose, the rates of occurrence of these events did not differ significantly from those of the placebo. In placebo-controlled trials of HIV-uninfected patients age 12 years and older who received Alinia Tablets for the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Giardia lamblia</span> or <span class="Italics">Cryptosporidium parvum</span>, less than 1% of patients discontinued therapy because of an adverse event.
</p>
<p>Adverse events occurring in less than 1% of the patients age 12 years and older participating in clinical trials of Alinia Tablets are listed below:
</p>
<p><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>.
</p>
<p><span class="Italics">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>.
</p>
<p><span class="Italics">Digestive System:</span> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>.
</p>
<p><span class="Italics">Urogenital System:</span> discolored urine, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">kidney pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> labia.
</p>
<p><span class="Italics">Metabolic &amp; Nutrition:</span> increased SGPT.
</p>
<p><span class="Italics">Hemic &amp; Lymphatic Systems:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>.
</p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.
</p>
<p><span class="Italics">Special Senses:</span> eye discoloration, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear ache</span>.
</p>
<p><span class="Italics">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>.
</p>
<p><span class="Italics">Cardiovascular System:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.
</p>
<p><span class="Italics">Muscular System:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">spontaneous bone fracture</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Alinia for Oral Suspension:</span> In controlled and uncontrolled clinical studies of 613 HIV-uninfected pediatric patients who received Alinia for Oral Suspension, the most frequent adverse events reported regardless of causality assessment were: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (7.8%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.1%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1.1%) and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (1.1%). These were typically mild and transient in nature. In placebo-controlled clinical trials, the rates of occurrence of these events did not differ significantly from those of the placebo. None of the 613 pediatric patients discontinued therapy because of adverse events.
</p>
<p>Adverse events occurring in less than 1% of the pediatric patients participating in clinical trials of Alinia for Oral Suspension are listed below:
</p>
<p><span class="Italics">Digestive System:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, appetite increase, enlarged salivary glands.
</p>
<p><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.
</p>
<p><span class="Italics">Metabolic &amp; Nutrition:</span> increased creatinine, increased SGPT.
</p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, sweat.
</p>
<p><span class="Italics">Special Senses:</span> eye discoloration (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow).
</p>
<p><span class="Italics">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>.
</p>
<p><span class="Italics">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.
</p>
<p><span class="Italics">Urogenital System:</span> discolored urine.
</p>
<p>The adverse events seen in adult patients treated with Alinia for Oral Suspension were similar to those observed in adult patients treated with Alinia Tablets.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s35"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">Information on nitazoxanide overdosage is not available. In acute studies in rodents and dogs, the oral LD<span class="Sub">50</span> was higher than 10,000 mg/kg. Single oral doses of up to 4,000 mg nitazoxanide have been administered to healthy adult volunteers without significant adverse effects. In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, gastric lavage may be appropriate soon after oral administration. Patients should be carefully observed and given symptomatic and supportive treatment.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s36"></a><a name="section-9"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION
</h1>
<table width="100%">
<col align="left" width="26.232%">
<col align="left" width="13.103%">
<col align="left" width="45.911%">
<col align="left" width="14.754%">
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">* Alinia Tablets and Alinia for Oral Suspension have not been studied for the treatment of <span class="Italics">Giardia lamblia</span> in HIV-infected or immunodeficient patients. Alinia Tablets and Alinia for Oral Suspension have not been shown to be superior to placebo for the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Cryptosporidium parvum</span> in HIV-infected or immunodeficient patients (see <span class="Bold"><a href="#s42">CLINICAL STUDIES</a></span>).
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="justify" valign="top"><span class="Bold">Indication</span></td>
<td class="Botrule Toprule" align="justify" valign="top"><span class="Bold">Age</span></td>
<td class="Botrule Toprule" align="left" valign="top"><span class="Bold">Dosage</span></td>
<td class="Botrule Toprule" align="center" valign="top"><span class="Bold">Duration</span></td>
</tr>
<tr>
<td align="left" rowspan="2" valign="top">Treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by Giardia lamblia or Cryptosporidium parvum*
</td>
<td align="justify" valign="top">1-3 years
</td>
<td align="left" valign="top">5 mL of Alinia for Oral Suspension<br>(100 mg nitazoxanide) every 12 hours with food
</td>
<td align="left" rowspan="2" valign="top">
<br><br><br>3 days
</td>
</tr>
<tr>
<td align="justify" valign="top">4-11 years
</td>
<td align="left" valign="top">10 mL of Alinia for Oral Suspension<br>(200 mg nitazoxanide) every 12 hours with food
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="justify" valign="top"></td>
<td class="Botrule" align="justify" valign="top">≥12 years
</td>
<td class="Botrule" align="left" valign="top">1 Alinia Tablet (500 mg nitazoxanide) every 12 hours with food <span class="Underline">or</span> 25 mL of Alinia for Oral Suspension (500 mg nitazoxanide) every 12 hours with food
</td>
<td class="Botrule" align="justify" valign="top"></td>
</tr>
</tbody>
</table>
<p class="First">A single Alinia tablet contains a greater amount of nitazoxanide than is recommended for pediatric dosing and should therefore not be used in pediatric patients 11 years or younger.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-10"></a><p></p>
<h1>DIRECTIONS FOR MIXING ALINIA FOR ORAL SUSPENSION
</h1>
<p class="First">Prepare a suspension at time of dispensing as follows: The amount of water required for preparation of the suspension is 48 mL. Tap bottle until all powder flows freely. Add approximately one-half of the total amount of water required for reconstitution and shake vigorously to suspend powder. Add remainder of water and again shake vigorously.
</p>
<p>The container should be kept tightly closed, and the suspension should be shaken well before each administration. The suspension may be stored for 7 days, after which any unused portion must be discarded.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s38"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Alinia Tablets</span> are round, yellow, film-coated tablets debossed with ALINIA on one side and 500 on the other side. Each tablet contains 500 mg of nitazoxanide. The tablets are packaged in HDPE bottles of 30 tablets.
</p>
<dl>
<dt> 
</dt>
<dd> Bottles of 30            NDC 67546-111-12
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-11.2"></a><p></p>
<p class="First"><span class="Bold">Alinia for Oral Suspension</span> is a pink-colored powder formulation that, when reconstituted as directed, contains 100 mg nitazoxanide/5 mL. The reconstituted suspension has a pink color and strawberry flavor. Alinia for Oral Suspension is available as:
</p>
<dl>
<dt> 
</dt>
<dd> Bottles of 60 mL       NDC 67546-212-21
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s41"></a><a name="section-11.3"></a><p></p>
<p class="First"><span class="Bold Underline">Storage and Stability</span>: Store the tablets, unsuspended powder, and the reconstituted oral suspension at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). [See USP Controlled Room Temperature]
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s42"></a><a name="section-12"></a><p></p>
<h1>CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-12.1"></a><p></p>
<h2>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> caused by </span><span class="Italics Underline">Giardia lamblia</span><span class="Underline"> in adults and adolescents 12 years of age or older:</span>
</h2>
<p class="First">In a double-blind, controlled study (Study 1) conducted in Peru and Egypt in adults and adolescents with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Giardia lamblia</span>, a three-day course of treatment with Alinia Tablets administered 500 mg BID was compared with a placebo tablet for 3 days. A third group of patients received open-label Alinia for Oral Suspension administered 500mg/25mL of suspension BID for 3 days. A second double-blind, controlled study (Study 2) conducted in Egypt in adults and adolescents with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Giardia lamblia</span> compared Alinia Tablets administered 500 mg BID for 3 days to a placebo tablet. For both of these studies, clinical response was evaluated 4 to 7 days following the end of treatment. A clinical response of 'well' was defined as 'no symptoms, no watery stools and no more than 2 soft stools with no <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span> within the past 24 hours' or 'no symptoms and no unformed stools within the past 48 hours.' The following clinical response rates were obtained:
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-12.2"></a><p></p>
<h2>Adult and Adolescent Patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Caused by <span class="Italics">Giardia lamblia </span>
</h2>
<a name="t300"></a><table width="100%">
<caption><span>Clinical Response Rates* 4 to 7 Days Post-therapy % (Number of Successes/Total)
</span></caption>
<col align="left" width="14.825%">
<col align="left" width="27.775%">
<col align="left" width="31.475%">
<col align="left" width="25.925%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote">* Includes all patients randomized with <span class="Italics">Giardia lamblia</span> as the sole pathogen. Patients failing to complete the studies were treated as failures.
</p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">¶</span> Clinical response rates statistically significantly higher when compared to placebo.
</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">§</span> The 95% confidence interval of the difference in response rates for the tablet and suspension is (-14%, 17%).
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="justify" valign="middle"></td>
<td class="Botrule" align="center" valign="middle">Alinia Tablets
</td>
<td class="Botrule" align="center" valign="middle">Alinia for Oral Suspension
</td>
<td class="Botrule" align="center" valign="top">Placebo Tablets
</td>
</tr>
<tr>
<td align="justify" valign="middle">Study 1
</td>
<td align="center" valign="middle">85% (46/54) <span class="Sup">¶ §</span>
</td>
<td align="center" valign="middle">83% (45/54) <span class="Sup">¶ §</span>
</td>
<td align="center" valign="middle">44% (12/27)
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="justify" valign="middle">Study 2
</td>
<td class="Botrule" align="center" valign="middle">100% (8/8)
</td>
<td class="Botrule" align="center" valign="middle">-
</td>
<td class="Botrule" align="center" valign="middle">30% (3/10)
</td>
</tr>
</tbody>
</table>
<p class="First">Some patients with 'well' clinical responses had <span class="Italics">Giardia lamblia</span> <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> in their stool samples 4 to 7 days following the end of treatment. The relevance of stool examination results in these patients is unknown. Patients should be managed based upon clinical response to treatment.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-12.3"></a><p></p>
<h2>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> caused by </span><span class="Italics Underline">Giardia lamblia</span><span class="Underline"> in pediatric patients 1 through 11 years of age:</span>
</h2>
<p class="First">In a randomized, controlled study conducted in Peru in 110 pediatric patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Giardia lamblia</span>, a three-day course of treatment with nitazoxanide (100 mg BID in pediatric patients ages 24-47 months, 200 mg BID in pediatric patients ages 4 through 11 years) was compared to a five-day course of treatment with metronidazole (125 mg BID in pediatric patients ages 2 through 5 years, 250 mg BID in pediatric patients ages 6 through 11 years). Clinical response was evaluated 7 to 10 days following initiation of treatment with a 'well' response defined as 'no symptoms, no watery stools and no more than 2 soft stools with no <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span> within the past 24 hours' or 'no symptoms and no unformed stools within the past 48 hours.' The following clinical cure rates were obtained:
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-12.4"></a><p></p>
<h2>Pediatric Patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Caused by <span class="Italics">Giardia lamblia </span>
</h2>
<a name="t301"></a><table width="100%">
<caption><span>Clinical Response Rates 7 to 10 Days Following Initiation of Therapy Intent-to-Treat and Per Protocol Analyses % (Number of Successes/Total), [95% Confidence Interval]
</span></caption>
<col align="left" width="26.782%">
<col align="left" width="26.782%">
<col align="left" width="28.582%">
<col align="left" width="17.854%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">†</span> Intent-to-treat analysis includes all patients randomized with patients not completing the study treated as failures.
</p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">¶</span> Per protocol analysis includes only patients who took all of their medication and completed the study. Seven patients in each treatment group missed at least 1 dose of medication and 1 in the metronidazole treatment group was lost to follow-up.
</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">§</span> 95% Confidence Interval on the difference in response rates (nitazoxanide-metronidazole).
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="left" valign="middle">Population
</td>
<td class="Botrule" align="center" valign="middle">Nitazoxanide (3 days)
</td>
<td class="Botrule" align="center" valign="middle">Metronidazole (5 days)
</td>
<td class="Botrule" align="center" valign="middle">95% <span class="Italics">CI</span> Diff<span class="Sup">§</span>
</td>
</tr>
<tr>
<td align="left" valign="middle">Intent-to-treat analysis<span class="Sup">†</span>
</td>
<td align="center" valign="middle">85% (47/55)
</td>
<td align="center" valign="middle">80% (44/55 )
</td>
<td align="center" valign="middle">[-9%, 20%]
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">Per protocol analysis<span class="Sup">¶</span>
</td>
<td class="Botrule" align="center" valign="middle">90% (43/48)
</td>
<td class="Botrule" align="center" valign="middle">83% (39/47 )
</td>
<td class="Botrule" align="center" valign="middle">[-8%, 21%]
</td>
</tr>
</tbody>
</table>
<p class="First">Some patients with 'well' clinical responses had <span class="Italics">Giardia lamblia</span> <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> in their stool samples 4 to 7 days following the end of treatment. The relevance of stool examination results in these patients is unknown. Patients should be managed based upon clinical response to treatment.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-12.5"></a><p></p>
<h2>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> caused by </span><span class="Italics Underline">Cryptosporidium parvum</span><span class="Underline"> in adults and adolescents 12 years of age or older:</span>
</h2>
<p class="First">In a double-blind, controlled study conducted in Egypt in adults and adolescents with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Cryptosporidium parvum</span>, a three-day course of treatment with Alinia Tablets administered 500 mg BID was compared with a placebo tablet for 3 days. A third group of patients received open-label Alinia for Oral Suspension administered 500mg/25mL of suspension BID for 3 days. Clinical response was evaluated 4 to 7 days following the end of treatment. A clinical response of 'well' was defined as 'no symptoms, no watery stools and no more than 2 soft stools within the past 24 hours' or 'no symptoms and no unformed stools within the past 48 hours.' The following clinical response rates were obtained:
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-12.6"></a><p></p>
<h2>Adult and Adolescent Patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Caused by <span class="Italics">Cryptosporidium parvum </span>
</h2>
<a name="t302"></a><table width="100%">
<caption><span>Clinical Response Rates 4 to 7 Days Post-therapy % (Number of Successes/Total)
</span></caption>
<col align="left" width="15.825%">
<col align="left" width="25.175%">
<col align="left" width="25.025%">
<col align="left" width="33.975%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote">* Includes all patients randomized with <span class="Italics">Cryptosporidium parvum</span> as the sole pathogen. Patients failing to complete the study were treated as failures.
</p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">¶</span> Clinical response rates statistically significantly higher when compared to placebo.
</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">§</span> The 95% confidence interval of the difference in response rates for the tablet and suspension is (-10%, 28%).
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle">Alinia Tablets
</td>
<td class="Botrule" align="center" valign="middle">Alinia Suspension
</td>
<td class="Botrule" align="center" valign="middle">Placebo Tablets
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">Intent-to-treat analysis*
</td>
<td class="Botrule" align="center" valign="middle">96% (27/28) <span class="Sup">¶ §</span>
</td>
<td class="Botrule" align="center" valign="middle">87% (27/31) <span class="Sup">¶ §</span>
</td>
<td class="Botrule" align="center" valign="middle">41% (11/27)
</td>
</tr>
</tbody>
</table>
<p class="First">In a second double-blind, placebo-controlled study of nitazoxanide tablets conducted in Egypt in adults and adolescents with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Cryptosporidium parvum</span> as the sole pathogen, clinical and parasitological response rates showed a similar trend to the first study. Clinical response rates, evaluated 2 to 6 days following the end of treatment, were 71% (15/21) in the nitazoxanide group and 42.9% (9/21) in the placebo group.
</p>
<p>Some patients with 'well' clinical responses had <span class="Italics">Cryptosporidium parvum</span> oocysts in their stool samples 4 to 7 days following the end of treatment. The relevance of stool examination results in these patients is unknown. Patients should be managed based upon clinical response to treatment.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-12.7"></a><p></p>
<h2>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> caused by </span><span class="Italics Underline">Cryptosporidium parvum</span><span class="Underline"> in pediatric patients 1 through 11 years of age:</span>
</h2>
<p class="First">In two double-blind, controlled studies in pediatric patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Cryptosporidium parvum</span>, a three-day course of treatment with nitazoxanide (100 mg BID in pediatric patients ages 12-47 months, 200 mg BID in pediatric patients ages 4 through 11 years) was compared with a placebo. One study was conducted in Egypt in outpatients ages 1 through 11 years with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Cryptosporidium parvum</span>. Another study was conducted in Zambia in malnourished pediatric patients admitted to the hospital with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by <span class="Italics">Cryptosporidium parvum</span>. Clinical response was evaluated 3 to 7 days post-therapy with a 'well' response defined as 'no symptoms, no watery stools and no more than 2 soft stools within the past 24 hours' or 'no symptoms and no unformed stools within the past 48 hours.' The following clinical response rates were obtained:
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-12.8"></a><p></p>
<h2>Pediatric Patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Caused by <span class="Italics">Cryptosporidium parvum</span>
</h2>
<a name="t303"></a><table width="100%">
<caption><span>Clinical Response Rates 3 to 7 Days Post-therapy, Intent-to-Treat Analyses % (Number of Successes/Total)
</span></caption>
<col align="left" width="53.567%">
<col align="left" width="21.433%">
<col align="left" width="25.000%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Italics">*</span> Clinical response rates statistically significantly higher compared to placebo.
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">¶</span> 60% considered severely <span class="product-label-link" type="condition" conceptid="435372" conceptname="Underweight">underweight</span>, 19% moderately <span class="product-label-link" type="condition" conceptid="435372" conceptname="Underweight">underweight</span>, 17% mild <span class="product-label-link" type="condition" conceptid="435372" conceptname="Underweight">underweight</span>.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="left" valign="middle">Population
</td>
<td class="Botrule" align="center" valign="middle">Nitazoxanide*
</td>
<td class="Botrule" align="center" valign="middle">Placebo
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Outpatient Study, age 1 - 11 years
</td>
<td class="Botrule" align="center" valign="middle">88% (21/24)
</td>
<td class="Botrule" align="center" valign="middle">38% (9/24)
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">Inpatient Study, Malnourished<span class="Sup">¶</span>, age 12-35 months
</td>
<td class="Botrule" align="center" valign="middle">56% (14/25)
</td>
<td class="Botrule" align="center" valign="middle">23% (5/22 )
</td>
</tr>
</tbody>
</table>
<p class="First">Some patients with 'well' clinical responses had <span class="Italics">Cryptosporidium</span> oocysts in their stool samples 3 to 7 days following the end of treatment. The relevance of stool examination results in these patients is unknown. Patients should be managed based upon clinical response to treatment.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-12.9"></a><p></p>
<h2>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> caused by </span><span class="Italics Underline">Cryptosporidium parvum</span><span class="Underline"> in AIDS patients:</span>
</h2>
<p class="First">A double-blind, placebo-controlled study did not produce clinical cure rates that were significantly different from the placebo control when conducted in hospitalized, severely malnourished pediatric patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immune deficiency syndrome</span> (AIDS) in Zambia. In this study, the pediatric patients received a three day course of nitazoxanide suspension (100 mg BID in pediatric patients ages 12-47 months, 200 mg BID in pediatric patients ages 4 through 11 years) and were evaluated for response four days after the end of treatment.
</p>
<p><span class="Bold">Rx Only<br></span>US Patents No. 5,578,621; 6,020,353; 5,968,961; 5,387,598; 6,117,894; 5,965,590. <br><span class="Bold">DATE OF ISSUANCE: November, 2013</span></p>
<p><span class="Bold">ROMARK Laboratories, L.C.</span><br>
									3000 Bayport Drive, Suite 200, Tampa, FL 33607<br>Telephone: 813-282-8544, Fax: 813-282-1162<br>E-mail: customer.service@romark.com<br>Web site: www.romark.com
</p>
<p>To report suspected adverse reactions, contact Romark Laboratories at 813-282-8544 or FDA at 1-800-FDA-1088 or "http://www.fda.gov/medwatch."</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s52"></a><a name="section-13"></a><p></p>
<p class="First">NDC 67546-111-12
</p>
<p>Alinia<span class="Sup">®</span></p>
<p>(nitazoxanide) tablets
</p>
<p>500 mg
</p>
<p>Rx only
</p>
<p>30 TABLETS
</p>
<div class="Figure">
<a name="f02"></a><img alt="Bottle label 30s
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56b1575a-dff4-4c5a-a159-2f858e7a0cb8&amp;name=ali01-0011-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s53"></a><a name="section-14"></a><p></p>
<p class="First">NDC 67546-111-12
</p>
<p>Alinia<span class="Sup">®</span></p>
<p>(nitazoxanide) tablets
</p>
<p>500 mg
</p>
<p>Romark Laboratories, L.C.
</p>
<p>Rx Only
</p>
<p>30 TABLETS
</p>
<div class="Figure">
<a name="f03"></a><img alt="Carton 30s
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56b1575a-dff4-4c5a-a159-2f858e7a0cb8&amp;name=ali01-0011-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s54"></a><a name="section-15"></a><p></p>
<p class="First">NDC 67546-111-17
</p>
<p>Alinia<span class="Sup">®</span></p>
<p>(nitazoxanide) tablets
</p>
<p>500 mg
</p>
<p>Rx Only
</p>
<p>2 TABLETS
</p>
<p>SAMPLE
</p>
<div class="Figure">
<a name="f04"></a><img alt="Sample 2s
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56b1575a-dff4-4c5a-a159-2f858e7a0cb8&amp;name=ali01-0011-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s55"></a><a name="section-16"></a><p></p>
<p class="First">NDC 67546-111-17
</p>
<p>Alinia<span class="Sup">®</span></p>
<p>(nitazoxanide) tablets
</p>
<p>500 mg
</p>
<p>SAMPLE NOT FOR RESALE
</p>
<p>Romark Laboratories, L.C.
</p>
<p>Rx Only
</p>
<p>2 TABLETS
</p>
<div class="Figure">
<a name="f05"></a><img alt="Sample Carton 2s
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56b1575a-dff4-4c5a-a159-2f858e7a0cb8&amp;name=ali01-0011-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s56"></a><a name="section-17"></a><p></p>
<p class="First">NDC 67546-212-21
</p>
<p>Alinia<span class="Sup">®</span></p>
<p>(nitazoxanide)
</p>
<p>for Oral Suspension
</p>
<p>100mg/5mL
</p>
<p>Reconstitute with 48mL water
</p>
<p>SHAKE WELL BEFORE USING
</p>
<p>Any unused portion must be
</p>
<p>discarded 7 days after mixing
</p>
<p>60 mL reconstituted
</p>
<p>Rx Only
</p>
<p>ROMARK LABORATORIES, L.C.
</p>
<div class="Figure">
<a name="f06"></a><img alt="Bottle Label Suspension
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56b1575a-dff4-4c5a-a159-2f858e7a0cb8&amp;name=ali01-0011-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s57"></a><a name="section-18"></a><p></p>
<p class="First">NDC 67546-212-21
</p>
<p>Alinia<span class="Sup">®</span></p>
<p>(nitazoxanide)
</p>
<p>for Oral Suspension
</p>
<p>100mg/5mL
</p>
<p>Reconstitute with 48mL water
</p>
<p>SHAKE WELL BEFORE USING
</p>
<p>Any unused portion must be discarded
</p>
<p>7 days after mixing
</p>
<p>60 mL reconstituted
</p>
<p>Rx Only
</p>
<p>Romark Laboratories, L.C.
</p>
<div class="Figure">
<a name="f07"></a><img alt="Carton Suspension
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56b1575a-dff4-4c5a-a159-2f858e7a0cb8&amp;name=ali01-0011-07.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALINIA 		
					</strong><br><span class="contentTableReg">nitazoxanide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67546-111</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>nitazoxanide</strong> (nitazoxanide) </td>
<td class="formItem">nitazoxanide</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium starch glycolate type A potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lecithin, soybean</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyvinyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C Yellow No. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ALINIA;500
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67546-111-12</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:67546-111-17</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021497</td>
<td class="formItem">07/21/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALINIA 		
					</strong><br><span class="contentTableReg">nitazoxanide powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67546-212</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>nitazoxanide</strong> (nitazoxanide) </td>
<td class="formItem">nitazoxanide</td>
<td class="formItem">100 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium benzoate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carboxymethylcellulose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>anhydrous citric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>trisodium citrate dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>maltodextrin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>modified corn starch (1-octenyl succinic anhydride)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>triacetin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Red No. 40</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67546-212-21</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021498</td>
<td class="formItem">11/22/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Romark Laboratories, LC
							(877685123)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions, L.L.C.</td>
<td class="formItem"></td>
<td class="formItem">829672745</td>
<td class="formItem">MANUFACTURE(67546-111, 67546-212)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lapicor NV</td>
<td class="formItem"></td>
<td class="formItem">370420271</td>
<td class="formItem">API MANUFACTURE(67546-111, 67546-212)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>51903bf9-4f7c-4150-b9b2-ee504272e324</div>
<div>Set id: 56b1575a-dff4-4c5a-a159-2f858e7a0cb8</div>
<div>Version: 9</div>
<div>Effective Time: 20131121</div>
</div>
</div> <div class="DistributorName">Romark Laboratories, LC</div></p>
</body></html>
